Prometheus up on positive data in inflammatory bowel disease trials

Prometheus Biosciences

07/12/2022 12:54

** Shares of biotech co Prometheus Biosciences Inc  RXDX.O 
rise 246.6% to $125 premarket  
    ** Co reports positive mid-stage data testing antibody
PRA023 in ulcerative colitis (UC) and Crohn's disease (CD)
treatment trials
    ** Both studies showed strong efficacy and favorable safety
results - RXDX
    ** Based on totality of data in these two studies, co
intends to advance PRA023 in late-stage trial for UC, CD in 2023
    ** UC is an inflammatory bowel disease while CD is a type of
inflammatory bowel disease that causes ulcers in digestive tract
    ** RXDX down 8.8% YTD, as of last close
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))